078650 — G9Pharma Co Balance Sheet
0.000.00%
- KR₩135m
- KR₩23bn
- KR₩679m
Annual balance sheet for G9Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 11,227 | 331 | 4,673 | 111 | 1,839 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 5,780 | 7,037 | 4,357 | 3,895 | 457 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 25,319 | 23,393 | 30,211 | 21,835 | 2,694 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 48,273 | 72,157 | 45,981 | 29,515 | 108 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 75,066 | 97,272 | 78,007 | 53,199 | 5,293 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 30,782 | 40,620 | 45,400 | 42,455 | 37,817 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 42,867 | 46,841 | 57,311 | 59,510 | 37,989 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 32,200 | 50,432 | 20,696 | -6,311 | -32,696 |
| Total Liabilities & Shareholders' Equity | 75,066 | 97,272 | 78,007 | 53,199 | 5,293 |
| Total Common Shares Outstanding |